Key result
Rivaroxaban linked to ~26% lower stroke or systemic embolism risk vs warfarin in NVAF and OSA.
Why the study?
AF and OSA frequently co-occur and increase cardiovascular risk, but data comparing clinical and economic outcomes of rivaroxaban versus warfarin in patients with both conditions were needed.
Does rivaroxaban reduce stroke, systemic embolism, major bleeding, and healthcare costs compared to warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea?
Cohort (n=14,765)
Yes
Does rivaroxaban reduce stroke, systemic embolism, major bleeding, and healthcare costs compared to warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea?
In patients with nonvalvular atrial fibrillation and obstructive sleep apnea, rivaroxaban was associated with a lower risk of stroke or systemic embolism and reduced healthcare costs compared to warfarin, without increasing major bleeding.
Answers are grounded in this paper and cite their sources.
Rivaroxaban was associated with lower stroke risk in NVAF with OSA; leaves open whether randomized trials will confirm these findings.
BACKGROUND: Atrial fibrillation (AF) and obstructive sleep apnea (OSA) are often comorbid and associated with increased risk of cardiovascular events such as stroke. We evaluated the effectiveness, safety, healthcare resource utilization, and costs of rivaroxaban versus warfarin in patients with nonvalvular AF (NVAF) and comorbid OSA. METHODS: Plus adjudicated claims database to evaluate patients with NVAF, OSA, and moderate-to-severe stroke risk who initiated rivaroxaban or warfarin between November 2011 and December 2022. We adjusted for potential confounders with propensity score overlap weighting. Primary endpoints were evaluated based on intent-to-treat (ITT) and on-treatment follow-up to compare stroke or systemic embolism risk, major bleeding risk, all-cause healthcare resource utilization (inpatient hospitalizations, emergency department visits, outpatient visits, and pharmacy fills), and costs (per patient per year [PPPY]) by treatment cohort. RESULTS: In total, 14,765 patients were included (9133 received rivaroxaban; 5632 received warfarin). Rivaroxaban significantly reduced stroke or systemic embolism versus warfarin by 26% (ITT-hazard ratio, 0.74 [95% CI 0.60-0.91]; P = 0.004) and 30% (on-treatment-hazard ratio, 0.70 [95% CI 0.55-0.89]; P = 0.004). Major bleeding was not significantly different between rivaroxaban and warfarin in either analysis. All-cause healthcare resource utilization was significantly reduced with rivaroxaban versus warfarin, leading to significantly reduced PPPY costs. CONCLUSIONS: Among patients with NVAF and OSA, rivaroxaban was associated with a significant reduction in stroke or systemic embolism risk versus warfarin with no difference in major bleeding. Rivaroxaban significantly reduced healthcare resource utilization and costs compared with warfarin, providing support for the use of rivaroxaban in this population.
No takes yet. Share an insight, caveat, or question.
Natale et al. (2024) conducted a cohort in Nonvalvular atrial fibrillation and obstructive sleep apnea (n=14,765). Rivaroxaban vs. Warfarin was evaluated on Incidence of stroke or systemic embolism (per 100 person-years) (HR 0.74, 95% CI 0.60-0.91, p=0.004). Rivaroxaban reduced the risk of stroke or systemic embolism by 26% compared to warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea.
Synapse has enriched 10 related papers. Consider them for comparative context: